BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Curtin N, Bányai K, Thaventhiran J, Le Quesne J, Helyes Z, Bai P. Repositioning PARP inhibitors for SARS-CoV-2 infection(COVID-19); a new multi-pronged therapy for acute respiratory distress syndrome? Br J Pharmacol 2020;177:3635-45. [PMID: 32441764 DOI: 10.1111/bph.15137] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 10.5] [Reference Citation Analysis]
Number Citing Articles
1 Anand U, Jakhmola S, Indari O, Jha HC, Chen ZS, Tripathi V, Pérez de la Lastra JM. Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update. Front Immunol 2021;12:658519. [PMID: 34276652 DOI: 10.3389/fimmu.2021.658519] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Curtin N, Bányai K, Thaventhiran J, Le Quesne J, Helyes Z, Bai P. Repositioning PARP inhibitors for SARS-CoV-2 infection(COVID-19); a new multi-pronged therapy for acute respiratory distress syndrome? Br J Pharmacol 2020;177:3635-45. [PMID: 32441764 DOI: 10.1111/bph.15137] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 10.5] [Reference Citation Analysis]
3 Yim J, Lim HH, Kwon Y. COVID-19 and pulmonary fibrosis: therapeutics in clinical trials, repurposing, and potential development. Arch Pharm Res 2021;44:499-513. [PMID: 34047940 DOI: 10.1007/s12272-021-01331-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Habeichi NJ, Tannous C, Yabluchanskiy A, Altara R, Mericskay M, Booz GW, Zouein FA. Insights into the modulation of the interferon response and NAD+ in the context of COVID-19. Int Rev Immunol 2021;:1-11. [PMID: 34378474 DOI: 10.1080/08830185.2021.1961768] [Reference Citation Analysis]
5 Tauber AL, Schweiker SS, Levonis SM. The potential association between PARP14 and SARS-CoV-2 infection (COVID-19). Future Med Chem 2021;13:587-92. [PMID: 33467912 DOI: 10.4155/fmc-2020-0226] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Dash S, Dash C, Pandhare J. Therapeutic Significance of microRNA-Mediated Regulation of PARP-1 in SARS-CoV-2 Infection. Noncoding RNA 2021;7:60. [PMID: 34698261 DOI: 10.3390/ncrna7040060] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Badawy AA. Immunotherapy of COVID-19 with poly (ADP-ribose) polymerase inhibitors: starting with nicotinamide. Biosci Rep 2020;40:BSR20202856. [PMID: 33063092 DOI: 10.1042/BSR20202856] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
8 Cioffi R, Sabetta G, Rabaiotti E, Bergamini A, Bocciolone L, Candotti G, Candiani M, Valabrega G, Mangili G, Pignata S; MITO group. Impact of COVID-19 on medical treatment patterns in gynecologic oncology: a MITO group survey. Int J Gynecol Cancer 2021;31:1363-8. [PMID: 34426526 DOI: 10.1136/ijgc-2021-002784] [Reference Citation Analysis]
9 Sipos A, Ujlaki G, Mikó E, Maka E, Szabó J, Uray K, Krasznai Z, Bai P. The role of the microbiome in ovarian cancer: mechanistic insights into oncobiosis and to bacterial metabolite signaling. Mol Med 2021;27:33. [PMID: 33794773 DOI: 10.1186/s10020-021-00295-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
10 Rawle DJ, Le TT, Dumenil T, Yan K, Tang B, Nguyen W, Watterson D, Modhiran N, Hobson-Peters J, Bishop C, Suhrbier A. ACE2-lentiviral transduction enables mouse SARS-CoV-2 infection and mapping of receptor interactions. PLoS Pathog 2021;17:e1009723. [PMID: 34214142 DOI: 10.1371/journal.ppat.1009723] [Reference Citation Analysis]
11 Schumann S, Kaiser A, Nicoletti F, Mangano K, Fagone P, van Wijk E, Yan Y, Schulz P, Ludescher B, Niedermaier M, von Wegerer J, Rauch P, Setz C, Schubert U, Brysch W. Immune-Modulating Drug MP1032 with SARS-CoV-2 Antiviral Activity In Vitro: A potential Multi-Target Approach for Prevention and Early Intervention Treatment of COVID-19. Int J Mol Sci 2020;21:E8803. [PMID: 33233817 DOI: 10.3390/ijms21228803] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Liontos M, Terpos E, Markellos C, Zagouri F, Briasoulis A, Katsiana I, Skafida E, Fiste O, Kunadis E, Andrikopoulou A, Kaparelou M, Koutsoukos K, Gavriatopoulou M, Kastritis E, Trougakos IP, Dimopoulos MA. Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors. Vaccines (Basel) 2021;9:1148. [PMID: 34696256 DOI: 10.3390/vaccines9101148] [Reference Citation Analysis]
13 Brown JM, Wasson MD, Marcato P. Triple-Negative Breast Cancer and the COVID-19 Pandemic: Clinical Management Perspectives and Potential Consequences of Infection. Cancers (Basel) 2021;13:296. [PMID: 33467411 DOI: 10.3390/cancers13020296] [Reference Citation Analysis]
14 Golubev AG. COVID-19: A Challenge to Physiology of Aging. Front Physiol 2020;11:584248. [PMID: 33343386 DOI: 10.3389/fphys.2020.584248] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
15 Sen R, Garbati M, Bryant K, Lu Y. Epigenetic mechanisms influencing COVID-19. Genome 2021;64:372-85. [PMID: 33395363 DOI: 10.1139/gen-2020-0135] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
16 Szabó Z, Marosvölgyi T, Szabó É, Bai P, Figler M, Verzár Z. The Potential Beneficial Effect of EPA and DHA Supplementation Managing Cytokine Storm in Coronavirus Disease. Front Physiol 2020;11:752. [PMID: 32636763 DOI: 10.3389/fphys.2020.00752] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
17 Stella A, Lamkanfi M, Portincasa P. Familial Mediterranean Fever and COVID-19: Friends or Foes? Front Immunol 2020;11:574593. [PMID: 33072117 DOI: 10.3389/fimmu.2020.574593] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
18 Tan A, Doig CL. NAD+ Degrading Enzymes, Evidence for Roles During Infection. Front Mol Biosci 2021;8:697359. [PMID: 34485381 DOI: 10.3389/fmolb.2021.697359] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Szántó M, Gupte R, Kraus WL, Pacher P, Bai P. PARPs in lipid metabolism and related diseases. Prog Lipid Res 2021;84:101117. [PMID: 34450194 DOI: 10.1016/j.plipres.2021.101117] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Cava C, Bertoli G, Castiglioni I. Potential drugs against COVID-19 revealed by gene expression profile, molecular docking and molecular dynamic simulation. Future Virol 2021. [PMID: 34306168 DOI: 10.2217/fvl-2020-0392] [Reference Citation Analysis]
21 Ma Z, Sun X, Zhao Z, Lu W, Guo Q, Wang S, You J, Zhang Y, Liu L. Risk of pneumonitis in cancer patients treated with PARP inhibitors: A meta-analysis of randomized controlled trials and a pharmacovigilance study of the FAERS database. Gynecol Oncol 2021;162:496-505. [PMID: 34023129 DOI: 10.1016/j.ygyno.2021.05.012] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Ummarino S, Hausman C, Di Ruscio A. The PARP Way to Epigenetic Changes. Genes (Basel) 2021;12:446. [PMID: 33804735 DOI: 10.3390/genes12030446] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
23 Tapryal N, Shahabi S, Chakraborty A, Hosoki K, Wakamiya M, Sarkar G, Sharma G, Cardenas VJ, Boldogh I, Sur S, Ghosh G, Hazra TK. Intrapulmonary administration of purified NEIL2 abrogates NF-κB-mediated inflammation. J Biol Chem 2021;296:100723. [PMID: 33932404 DOI: 10.1016/j.jbc.2021.100723] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]